Drug Profile
Trastuzumab biosimilar - Nichi-Iko Pharmaceutical/Aprogen
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Aprogen; Nichi-Iko Pharmaceutical
- Developer Nichi-Iko Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Breast-cancer in Japan (Parenteral)